We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

576 hedge funds and large institutions have $9.72B invested in BioMarin Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 226 increasing their positions, 200 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $91M | Put options by funds: $59.3M

13% more repeat investments, than reductions

Existing positions increased: 226 | Existing positions reduced: 200

1% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 74

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

1% less funds holding

Funds holding: 581 → 576 (-5)

4% less capital invested

Capital invested by funds: $10.1B → $9.72B (-$419M)

2.69% less ownership

Funds ownership: 96.18% → 93.49% (-2.7%)

Holders
576
Holders Change
-5
Holders Change %
-0.86%
% of All Funds
7.56%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
75
Increased
226
Reduced
200
Closed
74
Calls
$91M
Puts
$59.3M
Net Calls
+$31.7M
Net Calls Change
+$23.6M

Top Buyers

1
Capital Research Global Investors
Capital Research Global Investors
California
+$123M
2
Los Angeles Capital Management
Los Angeles Capital Management
California
+$60.3M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$51.8M
4
LSV Asset Management
LSV Asset Management
Illinois
+$46.5M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$38.4M

Top Sellers

1
Viking Global Investors
Viking Global Investors
Connecticut
-$227M
2
BlackRock
BlackRock
New York
-$112M
3
Morgan Stanley
Morgan Stanley
New York
-$59.9M
4
Ameriprise
Ameriprise
Minnesota
-$53.3M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$48M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.19B -$112M -1,955,625 -8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.01B -$24.1M -421,247 -2%
Primecap Management
3
Primecap Management
California
$825M -$31M -542,886 -3%
Dodge & Cox
4
Dodge & Cox
California
$795M -$24.1M -421,509 -3%
State Street
5
State Street
Massachusetts
$475M -$4.76M -83,152 -0.9%
Viking Global Investors
6
Viking Global Investors
Connecticut
$451M -$227M -3,966,432 -32%
AQR Capital Management
7
AQR Capital Management
Connecticut
$321M +$20.1M +351,536 +6%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$191M +$3.87M +67,682 +2%
Millennium Management
9
Millennium Management
New York
$142M -$11.8M -207,145 -7%
Capital Research Global Investors
10
Capital Research Global Investors
California
$137M +$123M +2,145,717 +548%
Goldman Sachs
11
Goldman Sachs
New York
$124M +$10.6M +185,355 +9%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$122M +$38.4M +671,566 +43%
Renaissance Technologies
13
Renaissance Technologies
New York
$103M +$4.96M +86,800 +5%
Northern Trust
14
Northern Trust
Illinois
$90M +$409K +7,157 +0.4%
UBS Group
15
UBS Group
Switzerland
$83.4M -$8.89M -155,423 -9%
Man Group
16
Man Group
United Kingdom
$80.9M +$941K +16,457 +1%
Charles Schwab
17
Charles Schwab
California
$75.7M -$9.07M -158,517 -10%
Squarepoint
18
Squarepoint
New York
$75.2M -$16.2M -283,923 -17%
Morgan Stanley
19
Morgan Stanley
New York
$74.8M -$59.9M -1,048,245 -43%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$74.3M +$392K +6,855 +0.5%
Los Angeles Capital Management
21
Los Angeles Capital Management
California
$72.2M +$60.3M +1,054,209 +379%
DnB Asset Management
22
DnB Asset Management
Norway
$69M +$8.86M +154,954 +14%
Ameriprise
23
Ameriprise
Minnesota
$66.5M -$53.3M -932,510 -43%
Deutsche Bank
24
Deutsche Bank
Germany
$58.8M +$11.3M +197,954 +22%
UBS AM
25
UBS AM
Illinois
$58.2M -$14M -245,619 -19%
1
2 3 4 5

BMRN Hedge Fund Activity: Q3 2025 in Review

576 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2025, worth a combined $9.72B — down 4.1% from $10.1B a quarter earlier.

Buyers outnumbered sellers: 75 funds opened new BMRN positions and 74 closed out — a net gain of 1 holder — while 226 added to existing stakes and 200 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $123M. The largest seller was Viking Global Investors, cutting an estimated $227M.

  • 576 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2025, down from 581 in Q2 2025.
  • Funds reported $9.72B of BioMarin Pharmaceuticals stock for Q3 2025, down 4.1% quarter-over-quarter.
  • 75 funds opened new BioMarin Pharmaceuticals positions in Q3 2025 and 74 closed out, a net change of +1 holder.
  • The largest BioMarin Pharmaceuticals buyer in Q3 2025 was Capital Research Global Investors, an estimated $123M added.
  • The largest BioMarin Pharmaceuticals seller in Q3 2025 was Viking Global Investors, an estimated $227M sold.

Based on aggregated 13F filings for Q3 2025.